Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hamlet BioPharma AB publ's PB Ratio or its related term are showing as below:
XSAT:HAMLET B'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 56.6
Current: 50
During the past 13 years, Hamlet BioPharma AB publ's highest PB Ratio was 56.60. The lowest was 0.00. And the median was 0.00.
XSAT:HAMLET B's PB Ratio is ranked worse than 97.78% of 1216
companies
in the Biotechnology industry
Industry Median: 2.945
vs XSAT:HAMLET B: 50.00
During the past 12 months, Hamlet BioPharma AB publ's average Book Value Per Share Growth Rate was -48.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hamlet BioPharma AB publ was 145.30% per year. The lowest was -71.70% per year. And the median was -16.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:HAMLET B vs VRTX, REGN, MRNA: PB Ratio Comparison
For the Biotechnology subindustry, Hamlet BioPharma AB publ's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamlet BioPharma AB publ PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hamlet BioPharma AB publ's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a PB Ratio of 50.00 as of Sep. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hamlet BioPharma AB publ and its competitors. According to the industry distribution chart, Hamlet BioPharma AB publ ranks #1189 out of 1216 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Hamlet BioPharma AB publ's PB Ratio too high?
Hamlet BioPharma AB publ's current PB Ratio is 50.00. The Biotechnology industry median PB Ratio is 2.95. Hamlet BioPharma AB publ's value of 50.00 is 1597.8% above this industry median. Based on the distribution chart, Hamlet BioPharma AB publ ranks #1189 out of 1216 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hamlet BioPharma AB publ ranks #1189 out of 1216 companies for PB Ratio. This places Hamlet BioPharma AB publ in the lower half of its industry. The industry median PB Ratio is 2.95. Hamlet BioPharma AB publ's value of 50.00 is 1597.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hamlet BioPharma AB publ's current PB Ratio of 50.00 is 1597.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hamlet BioPharma AB publ and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamlet BioPharma AB publ's current PB Ratio is 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a current PB Ratio of 50.00. The current PB Ratio is 50.00 and 1597.8% above the Biotechnology industry median of 2.95. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hamlet BioPharma AB publ (XSAT:HAMLET B), the current PB Ratio is 50.00 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:HAMLET B has been successfully added to your 
